• Khalid A Alswat, Hind I Fallatah, Bandar Al-Judaibi, Hussien A Elsiesy, Waleed K Al-Hamoudi, Adel N Qutub, Naif Alturaify, and Abdullah Al-Osaimi.
• Department of Medicine, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia. E-mail. kalswat@ksu.edu.sa.
• Saudi Med J. 2019 Jun 1; 40 (6): 531-540.

AbstractNon-alcoholic fatty liver disease (NAFLD) is a major national and international health burden. It is one of the most common liver diseases worldwide and the most common cause of abnormal liver enzymes in many developed countries. Non-alcoholic fatty liver disease is also known as an important cause of cryptogenic cirrhosis and second leading cause for liver transplantation. It is commonly associated with metabolic syndrome. Non-alcoholic steatohepatitis (NASH) is the progressive phenotype of NAFLD. In spite of promising performance of non-invasive tools, liver biopsy remains the gold standard test for NASH diagnosis. Over decades, many drugs have been investigated in phase 2 and 3; however, no approved therapy to date. Despite the alarming global rates of NAFLD, there are no local community-based studies on the prevalence of NAFLD or local practice guidelines on its management; this expert review aims to fill this gap.

33 keywords...

hide…